Show simple item record

dc.contributor.authorOh, D. Y.
dc.contributor.authorHe, A. R.
dc.contributor.authorQin, S.
dc.contributor.authorChen, L. T.
dc.contributor.authorOkusaka, T.
dc.contributor.authorVogel, A.
dc.contributor.authorKim, J. W.
dc.contributor.authorSuksombooncharoen, T.
dc.contributor.authorLee, M. A.
dc.contributor.authorKitano, M.
dc.contributor.authorBurris, H. A.
dc.contributor.authorBouattour, M.
dc.contributor.authorTanasanvimon, S.
dc.contributor.authorZaucha, R.
dc.contributor.authorAvallone, A.
dc.contributor.authorCundom, J.
dc.contributor.authorRokutanda, N.
dc.contributor.authorXiong, J.
dc.contributor.authorCohen, G.
dc.contributor.authorValle, Juan W
dc.date.accessioned2022-05-26T08:35:02Z
dc.date.available2022-05-26T08:35:02Z
dc.date.issued2022en
dc.identifier.citationOh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.. Vol. 40, Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022. p. 378–378.en
dc.identifier.doi10.1200/JCO.2022.40.4_suppl.378en
dc.identifier.urihttp://hdl.handle.net/10541/625226
dc.description.abstractBackground: BTC is a rare, heterogenous cancer with poor prognosis. Reports on immunogenic features of BTC suggest checkpoint inhibition may result in antitumor immune responses, and limited clinical activity has been seen with single agents in advanced settings. Durvalumab (PD-L1 inhibitor) + GemCis showed promising antitumor activity in advanced BTC in a phase 2 study. TOPAZ-1 (NCT03875235) is the first global phase 3 study to evaluate first-line immunotherapy + GemCis in advanced BTC. Methods: In this double-blind study, pts previously untreated for unresectable locally advanced, recurrent, or metastatic BTC were randomized 1:1 to receive durvalumab (1500 mg every 3 weeks [Q3W]) or placebo + GemCis (Gem 1000 mg/m2 and Cis 25 mg/m2 on Days 1 and 8 Q3W) for up to 8 cycles, followed by durvalumab (1500 mg Q4W) or placebo until disease progression or unacceptable toxicity. Randomization was stratified by disease status (initially unresectable, recurrent) and primary tumor location (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer). The primary objective was to assess overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety. Results: At data cutoff for this interim analysis (11 August 2021), 685 pts were randomized to durvalumab + GemCis (n=341) or placebo + GemCis (n=344; Table). The primary objective was met: durvalumab + GemCis significantly improved OS vs placebo + GemCis (hazard ratio [HR], 0.80; 95% confidence interval [CI], 0.66–0.97; p=0.021). PFS was also significantly improved with durvalumab vs placebo (HR, 0.75; 95% CI, 0.64–0.89; p=0.001). ORR was 26.7% with durvalumab and 18.7% with placebo. Grade 3/4 treatment-related adverse events (TRAEs) occurred in 62.7% of pts receiving durvalumab and 64.9% of pts receiving placebo. TRAEs led to discontinuation of any study medication in 8.9% of pts receiving durvalumab and 11.4% of pts receiving placebo. Conclusions: In pts with advanced BTC, durvalumab + GemCis significantly improved OS and PFS vs placebo + GemCis with manageable safety, indicating durvalumab + GemCis may be a new first-line standard of care regimen.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2022.40.4_suppl.378en
dc.titleA phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDivision of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea;en
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record